3B Future Health Fund

3B Future Health Fund is a venture capital firm focused on early-stage investments in healthcare companies that address significant unmet patient needs, particularly in oncology and rare diseases. The fund primarily targets start-up companies based in Europe, the United States, and Israel, seeking those with potential first-in-class assets, innovative insights, experienced management teams, and strong investor syndicates. Typically, 3B Future Health Fund makes its initial investments in companies raising Series A rounds, though it occasionally invests at earlier stages.

The fund's investment strategy emphasizes a diversified portfolio of 10-15 companies, with individual investments up to $12 million. It reserves capital for follow-on rounds and aims to hold investments for five to eight years, or fewer if value inflection points allow for earlier exits. The team comprises senior leaders with over 40 years of experience across the healthcare industry, including drug discovery, research and development, drug manufacturing, business development, licensing, and investment fund management.

Since its inception, 3B Future Health Fund has made several notable investments, including a €23 million Series A funding round for Sibylla Biotech in September 2022, and a €17.5 million funding award from the EIC Accelerator for iOnctura's clinical development of a novel pancreatic cancer therapy in December 2022. These investments reflect the fund's commitment to advancing innovative treatments in areas of high unmet medical need, aiming to bring life-changing therapies to patients worldwide.